Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
about
A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerTranscutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
P2860
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@ast
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@en
type
label
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@ast
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@en
prefLabel
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@ast
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@en
P2093
P2860
P356
P1476
Second-line paclitaxel in non- ...... ean Lung Cancer Working Party.
@en
P2093
A Efremidis
A Scherpereel
C G Alexopoulos
European Lung Cancer Working Party
J J Lafitte
J P Sculier
M C Berchier
M Paesmans
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603772
P407
P577
2007-05-01T00:00:00Z